millipore,
密理博,HCKP1-11K,MILLIPLEX MAP Human Immuno-Oncology Checkpoint Protein Panel 1 - Immuno-Oncology Multiplex Assay
| Replacement Information
|
| Replacement Information | This kit will replace HCKPMAG-11K |
重要规格表
| Analytes Available | Species Reactivity | Key Applications | Detection Methods |
|---|
| BTLA, CD27, CD28, CD40, CD80/B7-1, CD86/B7-2, CTLA-4, GITR, GITRL, HVEM, ICOS, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, TLR-2
| H
| Mplex
| Luminex xMAP
|
| Description
|
| Catalogue Number | HCKP1-11K |
| Replaces | HCKPMAG-11K |
| Trade Name |
|
| Description | MILLIPLEX® MAP Human Immuno-Oncology Checkpoint Protein Panel 1 - Immuno-Oncology Multiplex Assay |
| Overview | The MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 1 is a 17-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue culture samples: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2). |
| Background Information | Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies.
Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer. |
| Product Information
|
| Detection method | Luminex xMAP |
| Configuration | Design your multiplex kit by choosing available analytes within this panel. |
| Precision, % |
- Inter-assay: <15
- Intra-assay: <5
|
| Panel Type | MAGNETIC Circulating Cancer |
| Applications
|
| Application | The Human Immuno-Oncology Checkpoint Protein Panel 1 bead-based multiplex panel, using the Luminex xMAP technology, enables the simultaneous analysis of 17 immune checkpoint proteins in human serum, plasma and cell culture samples. |
| Key Applications |
|
| Application Notes | For optimal sensitivity, use an overnight (16-18 hour) incubation. Serum and plasma samples require (recommended) a 1:2 dilution with Assay Buffer. Tissue culture supernatants may be run neat or appropriately diluted in control medium. Each well requires 25 μL of sample, standard or control. |
| Biological Information
|
| Specificity | Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible. |
| Species Reactivity |
|
| Analytes Available |
- BTLA
- CD27
- CD28
- CD40
- CD80/B7-1
- CD86/B7-2
- CTLA-4
- GITR
- GITRL
- HVEM
- ICOS
- LAG-3
- PD-1
- PD-L1
- PD-L2
- TIM-3
- TLR-2
|
| Cross Reactivity | Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible. |
| Accuracy |
- BTLA: 95%
- CD27: 96%
- CD28: 95%
- CD40: 97%
- CD80/B7-1: 96%
- CD86/B7-2: 98%
- CTLA-4: 95%
- GITR: 90%
- GITRL: 103%
- HVEM: 98%
- ICOS: 100%
- LAG-3: 97%
- PD-1: 97%
- PD-L1: 97%
- PD-L2: 102%
- TIM-3: 98%
- TLR-2: 95%
|
| Physicochemical Information
|
| Sensitivity |
- (minDC+ 2SD)
- BTLA: 43.8 pg/mL
- CD27: 24.1 pg/mL
- CD28: 84.5 pg/mL
- CD40: 4.3 pg/mL
- CD80/B7-1: 11.2 pg/mL
- CD86/B7-2: 86.1 pg/mL
- CTLA-4: 9.3 pg/mL
- GITR: 18.8 pg/mL
- GITRL: 20.5 pg/mL
- HVEM: 0.8 pg/mL
- ICOS: 55.6 pg/mL
- LAG-3: 66.0 pg/mL
- PD-1: 13.7 pg/mL
- PD-L1: 1.3 pg/mL
- PD-L2: 46.6 pg/mL
- TIM-3: 1.5 pg/mL
- TLR-2: 24.1 pg/mL
|
| Standard Curve Range |
- BTLA: 49 – 200,000 pg/mL
- CD27: 24 – 100,000 pg/mL
- CD28: 244 – 1,000,000 pg/mL
- CD40: 5 – 20,000 pg/mL
- CD80/B7-1: 12 – 50,000 pg/mL
- CD86/B7-2: 73 – 300,000 pg/mL
- CTLA-4: 12 – 50,000 pg/mL
- GITR: 5 – 20,000 pg/mL
- GITRL: 24 – 100,000 pg/mL
- HVEM: 2 – 10,000 pg/mL
- ICOS: 49 – 200,000 pg/mL
- LAG-3: 122 – 500,000 pg/mL
- PD-1: 24 – 100,000 pg/mL
- PD-L1: 5 – 20,000 pg/mL
- PD-L2: 49 – 200,000 pg/mL
- TIM-3: 5 – 20,000 pg/mL
- TLR-2: 73 – 300,000 pg/mL
|
| Product Usage Statements
|
| Usage Statement |
- Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
|
| Storage and Shipping Information
|
| Storage Conditions | Recommended storage for kit components is 2 - 8°C. |
| Packaging Information
|
| Material Size | 96-well plate |
| Material Package | 96 well plate |
